Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum
- 25 September 2004
- journal article
- research article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 809 (1), 99-103
- https://doi.org/10.1016/j.jchromb.2004.06.003
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2003
- Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumorsInternational journal of clinical pharmacology and therapeutics, 2002
- BAY 43-9006: Early Clinical Data in Patients with Advanced Solid MalignanciesCurrent Pharmaceutical Design, 2002
- Targeting intracellular signal transduction: A new paradigm for a brave new world of molecularly targeted therapeuticsHematology/Oncology Clinics of North America, 2002
- High-performance liquid chromatographic assay validation of Manumycin A in mouse plasmaJournal of Chromatography B, 2002
- Method development and validation of a high-performance liquid chromatographic method for tramadol in human plasma using liquid–liquid extractionJournal of Chromatography B, 2002
- Discovery of a novel Raf kinase inhibitor.Endocrine-Related Cancer, 2001
- Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studiesEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991